Nektar Therapeutics

0.66
-0.04 (-5.71%)
At close: Feb 11, 2025, 3:59 PM
0.66
0.38%
After-hours Feb 11, 2025, 06:40 PM EST
undefined%
Bid 0.66
Market Cap 122.18M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.84
PE Ratio (ttm) -0.79
Forward PE n/a
Analyst Buy
Ask 0.66
Volume 4,017,590
Avg. Volume (20D) 1,903,726
Open 0.70
Previous Close 0.70
Day's Range 0.65 - 0.71
52-Week Range 0.63 - 1.93
Beta undefined

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and a...

Industry Biotechnology
Sector Healthcare
IPO Date May 3, 1994
Employees 137
Stock Exchange NASDAQ
Ticker Symbol NKTR

Analyst Forecast

According to 5 analyst ratings, the average rating for NKTR stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 503.86% from the latest price.

Buy 80.00%
Hold 20.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Nektar Therapeutics is scheduled to release its earnings on Mar 3, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
+3.55%
Nektar Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
3 months ago
+8.13%
Nektar Therapeutics shares are trading higher after the company announced it will sell its commercial PEGylation reagent manufacturing business to Ampersand Capital Partners.